{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:58:55Z","timestamp":1793843935665,"version":"4.6.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Peptide therapeutics are increasingly used in the treatment of disease, but their administration by injection reduces patient compliance and convenience, especially for chronic diseases. Thus, oral administration of a peptide therapeutic represents a significant advance in medicine, but is challenged by gastrointestinal instability and ineffective uptake into the circulation. Here, we have used glucagon-like peptide-1 (GLP-1) as a model peptide therapeutic for treating obesity-linked type 2 diabetes, a common chronic disease. We describe a comprehensive multidisciplinary approach leading to the development of MEDI7219, a GLP-1 receptor agonist (GLP-1RA) specifically engineered for oral delivery. Sites of protease\/peptidase vulnerabilities in GLP-1 were removed by amino acid substitution and the peptide backbone was bis-lipidated to promote MEDI7219 reversible plasma protein binding without affecting potency. A combination of sodium chenodeoxycholate and propyl gallate was used to enhance bioavailability of MEDI7219 at the site of maximal gastrointestinal absorption, targeted by enteric-coated tablets. This synergistic approach resulted in MEDI7219 bioavailability of\u2009~\u20096% in dogs receiving oral tablets. In a dog model of obesity and insulin resistance, MEDI7219 oral tablets significantly decreased food intake, body weight and glucose excursions, validating the approach. This novel approach to the development of MEDI7219 provides a template for the development of other oral peptide therapeutics.<\/jats:p>","DOI":"10.1038\/s41598-021-01750-0","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T11:06:20Z","timestamp":1637233580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease"],"prefix":"10.1038","volume":"11","author":[{"given":"Sergei","family":"Pechenov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jefferson","family":"Revell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Will","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Naylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneet","family":"Tyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandresh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihuan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton I.","family":"Rosenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kemal","family":"Balic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish","family":"Konkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Grimsby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Anand","family":"Subramony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,18]]},"reference":[{"key":"1750_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41573-019-0053-0","volume":"19","author":"DJ Drucker","year":"2020","unstructured":"Drucker, D. J. Advances in oral peptide therapeutics. Nat. Rev. Drug Discov. 19, 277\u2013289. https:\/\/doi.org\/10.1038\/s41573-019-0053-0 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1750_CR2","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1185\/03007990902905724","volume":"25","author":"AZ Fu","year":"2009","unstructured":"Fu, A. Z., Qiu, Y. & Radican, L. Impact of fear of insulin or fear of injection on treatment outcomes of patients with diabetes. Curr. Med. Res. Opin. 25, 1413\u20131420. https:\/\/doi.org\/10.1185\/03007990902905724 (2009).","journal-title":"Curr. Med. Res. Opin."},{"key":"1750_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/bja\/aeu013","volume":"113","author":"K Jenkins II","year":"2014","unstructured":"Jenkins, K. II. Needle phobia: a psychological perspective. Br. J. Anaesth. 113, 4\u20136. https:\/\/doi.org\/10.1093\/bja\/aeu013 (2014).","journal-title":"Br. J. Anaesth."},{"key":"1750_CR4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.4269\/ajtmh.2003.68.341","volume":"68","author":"Y Nir","year":"2003","unstructured":"Nir, Y., Paz, A., Sabo, E. & Potasman, I. Fear of injections in young adults: prevalence and associations. Am. J. Trop. Med. Hyg. 68, 341\u2013344 (2003).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1750_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ejpb.2017.03.015","volume":"115","author":"R Ismail","year":"2017","unstructured":"Ismail, R. & Csoka, I. Novel strategies in the oral delivery of antidiabetic peptide drugs - insulin, GLP 1 and its analogs. Eur. J. Pharm. Biopharm. 115, 257\u2013267. https:\/\/doi.org\/10.1016\/j.ejpb.2017.03.015 (2017).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"1750_CR6","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1177\/0145721709345773","volume":"35","author":"RR Rubin","year":"2009","unstructured":"Rubin, R. R., Peyrot, M., Kruger, D. F. & Travis, L. B. Barriers to insulin injection therapy: Patient and health care provider perspectives. Diab. Educ. 35, 1014\u20131022. https:\/\/doi.org\/10.1177\/0145721709345773 (2009).","journal-title":"Diab. Educ."},{"key":"1750_CR7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/193229680800200209","volume":"2","author":"J Randlov","year":"2008","unstructured":"Randlov, J. & Poulsen, J. U. How much do forgotten insulin injections matter to hemoglobin a1c in people with diabetes? A simulation study. J. Diab. Sci. Technol. 2, 229\u2013235. https:\/\/doi.org\/10.1177\/193229680800200209 (2008).","journal-title":"J. Diab. Sci. Technol."},{"key":"1750_CR8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jconrel.2018.08.032","volume":"10","author":"P Tyagi","year":"2018","unstructured":"Tyagi, P., Pechenov, S. & Subramony, J. A. Oral peptide delivery: translational challenges due to physiological effects. J. Control. Release 10, 167\u2013176 (2018).","journal-title":"J. Control. Release"},{"key":"1750_CR9","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.drudis.2021.01.020","volume":"26","author":"AT Zizzari","year":"2021","unstructured":"Zizzari, A. T., Pliatsika, D., Gall, F. M., Fischer, T. & Riedl, R. New perspectives in oral peptide delivery. Drug Discov. Today 26, 1097\u20131105. https:\/\/doi.org\/10.1016\/j.drudis.2021.01.020 (2021).","journal-title":"Drug Discov. Today"},{"key":"1750_CR10","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.joca.2014.12.019","volume":"23","author":"MA Karsdal","year":"2015","unstructured":"Karsdal, M. A. et al. Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials. Osteoarth. Cartil. 23, 532\u2013543. https:\/\/doi.org\/10.1016\/j.joca.2014.12.019 (2015).","journal-title":"Osteoarth. Cartil."},{"key":"1750_CR11","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1210\/jc.2014-4113","volume":"100","author":"S Melmed","year":"2015","unstructured":"Melmed, S. et al. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J. Clin. Endocrinol. Metab 100, 1699\u20131708. https:\/\/doi.org\/10.1210\/jc.2014-4113 (2015).","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"1750_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059524","volume":"8","author":"R Eldor","year":"2013","unstructured":"Eldor, R., Arbit, E., Corcos, A. & Kidron, M. Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study. PLoS ONE 8, e59524. https:\/\/doi.org\/10.1371\/journal.pone.0059524 (2013).","journal-title":"PLoS ONE"},{"key":"1750_CR13","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1016\/j.apsb.2020.12.022","volume":"11","author":"Z Zhang","year":"2021","unstructured":"Zhang, Z., Lu, Y., Qi, J. & Wu, W. An update on oral drug delivery via intestinal lymphatic transport. Acta Pharm Sin B 11, 2449\u20132468. https:\/\/doi.org\/10.1016\/j.apsb.2020.12.022 (2021).","journal-title":"Acta Pharm Sin B"},{"key":"1750_CR14","unstructured":"Vol, A. & Gribova, O. Oshadi Drug Administration Ltd. Methods and compositions for oral administration of protein and peptide therapeutic agents. US9949924B2."},{"key":"1750_CR15","doi-asserted-by":"publisher","unstructured":"Ali Khan, A., Mudassir, J., Mohtar, N. & Darwis, Y. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int J Nanomedicine 8, 2733\u20132744. https:\/\/doi.org\/10.2147\/IJN.S41521 (2013).","DOI":"10.2147\/IJN.S41521"},{"key":"1750_CR16","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.jconrel.2021.09.002","volume":"338","author":"P Tyagi","year":"2021","unstructured":"Tyagi, P. et al. Targeted oral peptide delivery using multi-unit particulates: Drug and permeation enhancer layering approach. J Control Release 338, 784\u2013791. https:\/\/doi.org\/10.1016\/j.jconrel.2021.09.002 (2021).","journal-title":"J Control Release"},{"key":"1750_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-021-00938-1,10.1007\/s13346-021-00938-1","author":"AK Dhalla","year":"2021","unstructured":"Dhalla, A. K. et al. A robotic pill for oral delivery of biotherapeutics: safety, tolerability, and performance in healthy subjects. Drug Deliv. Transl. Res. https:\/\/doi.org\/10.1007\/s13346-021-00938-1,10.1007\/s13346-021-00938-1 (2021).","journal-title":"Drug Deliv. Transl. Res."},{"key":"1750_CR18","doi-asserted-by":"publisher","unstructured":"Aran, K. et al. An oral microjet vaccination system elicits antibody production in rabbits. Sci. Transl. Med. 9, eaaf6413. https:\/\/doi.org\/10.1126\/scitranslmed.aaf6413 (2017).","DOI":"10.1126\/scitranslmed.aaf6413"},{"key":"1750_CR19","doi-asserted-by":"publisher","unstructured":"Huntsman, M. et al. Development of a novel drug delivery system to deliver drugs directly to the colonic mucosa, resulting in improved efficacy and reduced systemic exposure for the treatment of ulcerative colitis. Crohn's & Colitis 360 otab045. https:\/\/doi.org\/10.1093\/crocol\/otab1045 (2021).","DOI":"10.1093\/crocol\/otab1045"},{"key":"1750_CR20","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.addr.2017.01.006","volume":"112","author":"S Pechenov","year":"2017","unstructured":"Pechenov, S., Bhattacharjee, H., Yin, D., Mittal, S. & Subramony, J. A. Improving drug-like properties of insulin and GLP-1 via molecule design and formulation and improving diabetes management with device & drug delivery. Adv. Drug. Deliv. Rev. 112, 106\u2013122. https:\/\/doi.org\/10.1016\/j.addr.2017.01.006 (2017).","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"1750_CR21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","volume":"30","author":"TD Muller","year":"2019","unstructured":"Muller, T. D. et al. Glucagon-like peptide 1 (GLP-1). Mol. Metab. 30, 72\u2013130. https:\/\/doi.org\/10.1016\/j.molmet.2019.09.010 (2019).","journal-title":"Mol. Metab."},{"key":"1750_CR22","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/postgradmedj-2019-137186","volume":"96","author":"K Sheahan","year":"2020","unstructured":"Sheahan, K., Wahlberg, E. & Gilbert, M. An overview of GLP-1 agnostics and recent cardiovascular outcomes trials. Postgrad. Med. J. 96, 156\u2013161. https:\/\/doi.org\/10.1136\/postgradmedj-2019-137186 (2020).","journal-title":"Postgrad. Med. J."},{"key":"1750_CR23","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"284","author":"JPH Wilding","year":"2021","unstructured":"Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 284, 989\u20131002 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1750_CR24","unstructured":"US Food and Drug Administration. FDA approves first oral GLP-1 treatment for type 2 diabetes. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-oral-glp-1-treatment-type-2-diabetes. Accessed March 09, 2021."},{"key":"1750_CR25","unstructured":"Electronic Medicines Compendium. Rybelsus summary of product characteristics. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/11507\/smpc. Accessed March 09, 2021."},{"key":"1750_CR26","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1210\/jc.2002-021479","volume":"88","author":"TP Vahl","year":"2003","unstructured":"Vahl, T. P., Paty, B. W., Fuller, B. D., Prigeon, R. L. & D\u2019Alessio, D. A. Effects of GLP-1-(7\u201336)NH2, GLP-1-(7\u201337), and GLP-1-(9\u201336)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J. Clin. Endocrinol. Metab. 88, 1772\u20131779. https:\/\/doi.org\/10.1210\/jc.2002-021479 (2003).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1750_CR27","doi-asserted-by":"publisher","first-page":"6275","DOI":"10.1016\/S0021-9258(17)37366-0","volume":"269","author":"K Adelhorst","year":"1994","unstructured":"Adelhorst, K., Hedegaard, B. B., Knudsen, L. B. & Kirk, O. Structure-activity studies of glucagon-like peptide-1. J. Biol. Chem. 269, 6275\u20136278 (1994).","journal-title":"J. Biol. Chem."},{"key":"1750_CR28","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.2337\/dc14-1984","volume":"38","author":"JJ Meier","year":"2015","unstructured":"Meier, J. J. et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: A randomized, open-label trial. Diabetes Care 38, 1263\u20131273. https:\/\/doi.org\/10.2337\/dc14-1984 (2015).","journal-title":"Diabetes Care"},{"key":"1750_CR29","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/mp.2017.187","volume":"23","author":"L Lopez-Ferreras","year":"2018","unstructured":"Lopez-Ferreras, L. et al. Lateral hypothalamic GLP-1 receptors are critical for the control of food reinforcement, ingestive behavior and body weight. Mol. Psychiatry 23, 1157\u20131168. https:\/\/doi.org\/10.1038\/mp.2017.187 (2018).","journal-title":"Mol. Psychiatry"},{"key":"1750_CR30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2337\/db18-0317","volume":"68","author":"Y Zhang","year":"2019","unstructured":"Zhang, Y. et al. GLP-1 receptor in pancreatic alpha-cells regulates glucagon secretion in a glucose-dependent bidirectional manner. Diabetes 68, 34\u201344. https:\/\/doi.org\/10.2337\/db18-0317 (2019).","journal-title":"Diabetes"},{"key":"1750_CR31","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2017.14752","volume":"318","author":"M Davies","year":"2017","unstructured":"Davies, M. et al. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: A randomized clinical trial. JAMA 318, 1460\u20131470. https:\/\/doi.org\/10.1001\/jama.2017.14752 (2017).","journal-title":"JAMA"},{"key":"1750_CR32","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1530\/eje.0.1460863","volume":"146","author":"H Hui","year":"2002","unstructured":"Hui, H., Farilla, L., Merkel, P. & Perfetti, R. The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. Eur. J. Endocrinol. 146, 863\u2013869. https:\/\/doi.org\/10.1530\/eje.0.1460863 (2002).","journal-title":"Eur. J. Endocrinol."},{"key":"1750_CR33","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1210\/jc.2002-021053","volume":"88","author":"T Vilsboll","year":"2003","unstructured":"Vilsboll, T., Agerso, H., Krarup, T. & Holst, J. J. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J. Clin. Endocrinol. Metab. 88, 220\u2013224. https:\/\/doi.org\/10.1210\/jc.2002-021053 (2003).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"Suppl 2","key":"1750_CR34","doi-asserted-by":"publisher","first-page":"S279","DOI":"10.2337\/dc11-s231","volume":"34","author":"AJ Garber","year":"2011","unstructured":"Garber, A. J. Long-acting glucagon-like peptide 1 receptor agonists: A review of their efficacy and tolerability. Diab. Care 34(Suppl 2), S279\u2013S284. https:\/\/doi.org\/10.2337\/dc11-s231 (2011).","journal-title":"Diab. Care"},{"key":"1750_CR35","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/s0014-2999(96)00795-9","volume":"318","author":"LB Knudsen","year":"1996","unstructured":"Knudsen, L. B. & Pridal, L. Glucagon-like peptide-1-(9\u201336) amide is a major metabolite of glucagon-like peptide-1-(7\u201336) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur. J. Pharmacol. 318, 429\u2013435. https:\/\/doi.org\/10.1016\/s0014-2999(96)00795-9 (1996).","journal-title":"Eur. J. Pharmacol."},{"key":"1750_CR36","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/s0196-9781(97)00123-x","volume":"18","author":"K Hupe-Sodmann","year":"1997","unstructured":"Hupe-Sodmann, K. et al. Endoproteolysis of glucagon-like peptide (GLP)-1 (7\u201336) amide by ectopeptidases in RINm5F cells. Peptides 18, 625\u2013632. https:\/\/doi.org\/10.1016\/s0196-9781(97)00123-x (1997).","journal-title":"Peptides"},{"key":"1750_CR37","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/j.1432-1033.1993.tb17986.x","volume":"214","author":"R Mentlein","year":"1993","unstructured":"Mentlein, R., Gallwitz, B. & Schmidt, W. E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7\u201336)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214, 829\u2013835. https:\/\/doi.org\/10.1111\/j.1432-1033.1993.tb17986.x (1993).","journal-title":"Eur. J. Biochem."},{"key":"1750_CR38","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.addr.2020.05.007","volume":"157","author":"DJ Brayden","year":"2020","unstructured":"Brayden, D. J., Hill, T. A., Fairlie, D. P., Maher, S. & Mrsny, R. J. Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches. Adv. Drug. Deliv. Rev. 157, 2\u201336. https:\/\/doi.org\/10.1016\/j.addr.2020.05.007 (2020).","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"1750_CR39","doi-asserted-by":"publisher","first-page":"923","DOI":"10.3390\/biom3040923","volume":"3","author":"JA Motyan","year":"2013","unstructured":"Motyan, J. A., Toth, F. & Tozser, J. Research applications of proteolytic enzymes in molecular biology. Biomolecules 3, 923\u2013942. https:\/\/doi.org\/10.3390\/biom3040923 (2013).","journal-title":"Biomolecules"},{"key":"1750_CR40","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s001250050903","volume":"41","author":"CF Deacon","year":"1998","unstructured":"Deacon, C. F. et al. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetalogia 41, 271\u2013278 (1998).","journal-title":"Diabetalogia"},{"key":"1750_CR41","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/cbdv.200890112","volume":"5","author":"S Aravinda","year":"2008","unstructured":"Aravinda, S., Shamala, N. & Balaram, P. Aib residues in peptaibiotics and synthetic sequences: analysis of nonhelical conformations. Chem. Biodivers. 5, 1238\u20131262. https:\/\/doi.org\/10.1002\/cbdv.200890112 (2008).","journal-title":"Chem. Biodivers."},{"key":"1750_CR42","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1021\/acsmedchemlett.8b00226","volume":"9","author":"EM Bech","year":"2018","unstructured":"Bech, E. M., Pedersen, S. L. & Jensen, K. J. Chemical strategies for half-life extension of biopharmaceuticals: Lipidation and its alternatives. ACS Med. Chem. Lett. 9, 577\u2013580. https:\/\/doi.org\/10.1021\/acsmedchemlett.8b00226 (2018).","journal-title":"ACS Med. Chem. Lett."},{"key":"1750_CR43","doi-asserted-by":"publisher","unstructured":"Knudsen, L. B. & Lau, J. The discovery and development of liraglutide and semaglutide. Front. Endocrinol. (Lausanne) 10, 155. https:\/\/doi.org\/10.3389\/fendo.2019.00155 (2019).","DOI":"10.3389\/fendo.2019.00155"},{"key":"1750_CR44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1089\/dia.2019.0185","volume":"22","author":"JD Bucheit","year":"2020","unstructured":"Bucheit, J. D. et al. Oral semaglutide: A review of the first oral glucagon-like peptide 1 receptor agonist. Diab. Technol. Ther. 22, 10\u201318. https:\/\/doi.org\/10.1089\/dia.2019.0185 (2020).","journal-title":"Diab. Technol. Ther."},{"key":"1750_CR45","doi-asserted-by":"publisher","unstructured":"Buckley, S. T. et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci. Transl. Med. 10, eaar7047. https:\/\/doi.org\/10.1126\/scitranslmed.aar7047 (2018).","DOI":"10.1126\/scitranslmed.aar7047"},{"key":"1750_CR46","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1208\/s12249-014-0172-1","volume":"15","author":"D Becker","year":"2014","unstructured":"Becker, D. et al. Novel orally swallowable IntelliCap device to quantify regional drug absorption in human GI tract using diltiazem as model drug. AAPS PharmSciTech 15, 1490\u20131497. https:\/\/doi.org\/10.1208\/s12249-014-0172-1 (2014).","journal-title":"AAPS PharmSciTech"},{"key":"1750_CR47","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.cardiores.2003.11.027","volume":"61","author":"LA Nikolaidis","year":"2004","unstructured":"Nikolaidis, L. A. et al. The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. Cardiovasc. Res. 61, 297\u2013306. https:\/\/doi.org\/10.1016\/j.cardiores.2003.11.027 (2004).","journal-title":"Cardiovasc. Res."},{"key":"1750_CR48","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/nrendo.2017.161","volume":"14","author":"M Kleinert","year":"2018","unstructured":"Kleinert, M. et al. Animal models of obesity and diabetes mellitus. Nat. Rev. Endocrinol. 14, 140\u2013162. https:\/\/doi.org\/10.1038\/nrendo.2017.161 (2018).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1750_CR49","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","volume":"3","author":"DJ Drucker","year":"2006","unstructured":"Drucker, D. J. The biology of incretin hormones. Cell Metab. 3, 153\u2013165. https:\/\/doi.org\/10.1016\/j.cmet.2006.01.004 (2006).","journal-title":"Cell Metab."},{"key":"1750_CR50","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/papr.12130","volume":"14","author":"RB Raffa","year":"2014","unstructured":"Raffa, R. B., Pergolizzi, J. V. Jr., Taylor, R. Jr., Decker, J. F. & Patrick, J. T. Acetaminophen (paracetamol) oral absorption and clinical influences. Pain Pract. 14, 668\u2013677. https:\/\/doi.org\/10.1111\/papr.12130 (2014).","journal-title":"Pain Pract."},{"key":"1750_CR51","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2337\/db13-1764","volume":"63","author":"J Tong","year":"2014","unstructured":"Tong, J. & D\u2019Alessio, D. Give the receptor a brake: slowing gastric emptying by GLP-1. Diabetes 63, 407\u2013409. https:\/\/doi.org\/10.2337\/db13-1764 (2014).","journal-title":"Diabetes"},{"key":"1750_CR52","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s11154-014-9289-5","volume":"15","author":"M Shah","year":"2014","unstructured":"Shah, M. & Vella, A. Effects of GLP-1 on appetite and weight. Rev. Endocr. Metab. Disord. 15, 181\u2013187. https:\/\/doi.org\/10.1007\/s11154-014-9289-5 (2014).","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"1750_CR53","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/279530","volume":"2011","author":"CS Marathe","year":"2011","unstructured":"Marathe, C. S., Rayner, C. K., Jones, K. L. & Horowitz, M. Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Exp. Diabetes Res. 2011, 279530. https:\/\/doi.org\/10.1155\/2011\/279530 (2011).","journal-title":"Exp. Diabetes Res."},{"key":"1750_CR54","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1385\/MB:33:3:239","volume":"33","author":"M Amblard","year":"2006","unstructured":"Amblard, M., Fehrentz, J. A., Martinez, J. & Subra, G. Methods and protocols of modern solid phase peptide synthesis. Mol. Biotechnol. 33, 239\u2013254. https:\/\/doi.org\/10.1385\/MB:33:3:239 (2006).","journal-title":"Mol. Biotechnol."},{"key":"1750_CR55","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1023\/a:1011910801212","volume":"15","author":"E Galia","year":"1998","unstructured":"Galia, E. et al. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. 15, 698\u2013705. https:\/\/doi.org\/10.1023\/a:1011910801212 (1998).","journal-title":"Pharm. Res."},{"key":"1750_CR56","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/978-1-61779-191-8_9","volume":"763","author":"B Press","year":"2011","unstructured":"Press, B. Optimization of the Caco-2 permeability assay to screen drug compounds for intestinal absorption and efflux. Methods. Mol. Biol. 763, 139\u2013154. https:\/\/doi.org\/10.1007\/978-1-61779-191-8_9 (2011).","journal-title":"Methods. Mol. Biol."},{"key":"1750_CR57","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/(SICI)1096-9888(200001)35:1<71::AID-JMS915>3.0.CO;2-5","volume":"35","author":"Z Wang","year":"2000","unstructured":"Wang, Z., Hop, C. E., Leung, K. H. & Pang, J. Determination of in vitro permeability of drug candidates through a caco-2 cell monolayer by liquid chromatography\/tandem mass spectrometry. J. Mass Spectrom. 35, 71\u201376. https:\/\/doi.org\/10.1002\/(SICI)1096-9888(200001)35:1%3c71::AID-JMS915%3e3.0.CO;2-5 (2000).","journal-title":"J. Mass Spectrom."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01750-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01750-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01750-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T17:50:44Z","timestamp":1670089844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01750-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1750"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-01750-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,18]]},"assertion":[{"value":"28 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.R., S.W., J.N., P.T., C.P., L.L., Y.H., A.I.R., J.A.S. are employees and shareholders of AstraZeneca. S.P., L.T., K.B., A.K., J.G. are former employees and shareholders of AstraZeneca.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22521"}}